An old bull-bear debate is finally settled
Back in the early 2010s, the biotech corner of Twitter was fighting about weight loss. Arena Pharmaceuticals was moving toward approval with a drug called Belviq. Bulls contended the drug was a blockbuster in the making. Bears argued that its ties to tumor growth in rats would doom its prospects.
Cut to yesterday, and Belviq is getting pulled from shelves. The Japanese drug maker Eisai, which acquired Belviq from Arena in 2017, agreed to withdraw the drug from the U.S. market after the FDA expressed concerns about an increased occurrence of cancer reported in people who used the product, STAT’s Adam Feuerstein reports. A large post-marketing study found that more patients who took Belviq developed cancer than those on placebo.
Belviq never made much commercial noise in its eight years on the market. Sales added up to just $41 million in the first nine months of last year.
Read more.
Cut to yesterday, and Belviq is getting pulled from shelves. The Japanese drug maker Eisai, which acquired Belviq from Arena in 2017, agreed to withdraw the drug from the U.S. market after the FDA expressed concerns about an increased occurrence of cancer reported in people who used the product, STAT’s Adam Feuerstein reports. A large post-marketing study found that more patients who took Belviq developed cancer than those on placebo.
Belviq never made much commercial noise in its eight years on the market. Sales added up to just $41 million in the first nine months of last year.
Read more.
.png)
No hay comentarios:
Publicar un comentario